Should I buy or sell BioMarin Pharmaceutical stock right now?

19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last twelve months. There are currently 7 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BMRN shares. View BMRN analyst ratings or view top-rated stocks .

What is BioMarin Pharmaceutical's stock price target for 2024?

19 equities research analysts have issued 12 month target prices for BioMarin Pharmaceutical's shares. Their BMRN share price targets range from $78.00 to $185.00. On average, they anticipate the company's stock price to reach $107.61 in the next year. This suggests a possible upside of 17.6% from the stock's current price. View analysts price targets for BMRN or view top-rated stocks among Wall Street analysts .

How have BMRN shares performed in 2024?

BioMarin Pharmaceutical's stock was trading at $96.42 on January 1st, 2024. Since then, BMRN stock has decreased by 5.1% and is now trading at $91.51. View the best growth stocks for 2024 here .

When is BioMarin Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024. View our BMRN earnings forecast .

How can I listen to BioMarin Pharmaceutical's earnings call?

BioMarin Pharmaceutical will be holding an earnings conference call on Wednesday, April 24th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 609-800-9909 with passcode "1816377".

How were BioMarin Pharmaceutical's earnings last quarter?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) posted its quarterly earnings results on Thursday, February, 22nd. The biotechnology company reported $0.49 EPS for the quarter, beating analysts' consensus estimates of $0.45 by $0.05. The biotechnology company had revenue of $646.21 million for the quarter, compared to the consensus estimate of $639.53 million. BioMarin Pharmaceutical had a trailing twelve-month return on equity of 5.01% and a net margin of 6.93%. The company's revenue for the quarter was up 20.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.11 earnings per share.

What ETFs hold BioMarin Pharmaceutical's stock?

ETFs with the largest weight of BioMarin Pharmaceutical (NASDAQ:BMRN) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE) , Global X Genomics & Biotechnology ETF (GNOM) , First Trust NYSE Arca Biotechnology Index Fund (FBT) , Goldman Sachs Future Health Care Equity ETF (GDOC) , VanEck Biotech ETF (BBH) , BNY Mellon Innovators ETF (BKIV) , Motley Fool Mid-Cap Growth ETF (TMFM) and First Trust Innovation Leaders ETF (ILDR) .

What guidance has BioMarin Pharmaceutical issued on next quarter's earnings?

BioMarin Pharmaceutical issued an update on its FY 2024 earnings guidance on Thursday, February, 22nd. The company provided earnings per share guidance of 2.600-2.800 for the period, compared to the consensus EPS estimate of 1.960. The company issued revenue guidance of $2.7 billion-$2.8 billion, compared to the consensus revenue estimate of $2.8 billion.

What is Jean-Jacques Bienaimé's approval rating as BioMarin Pharmaceutical's CEO?

228 employees have rated BioMarin Pharmaceutical Chief Executive Officer Jean-Jacques Bienaimé on Glassdoor.com . Jean-Jacques Bienaimé has an approval rating of 94% among the company's employees. This puts Jean-Jacques Bienaimé in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at BioMarin Pharmaceutical to a friend.

What other stocks do shareholders of BioMarin Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI) , (MDVN) (MDVN) , Incyte (INCY) , First Solar (FSLR) , United Airlines (UAL) , Dynavax Technologies (DVAX) , Micron Technology (MU) , Vertex Pharmaceuticals (VRTX) , (KITE) (KITE) and Freeport-McMoRan (FCX) .

Who are BioMarin Pharmaceutical's major shareholders?

BioMarin Pharmaceutical's stock is owned by many different retail and institutional investors. Top institutional investors include Gateway Investment Advisers LLC (0.01%), Banque Cantonale Vaudoise (0.01%), Tealwood Asset Management Inc. (0.01%) and Park Avenue Securities LLC (0.00%). Insiders that own company stock include Brian Mueller , Charles Greg Guyer , Dennis Slamon , Erin Burkhart, George Eric Davis , Henry J Fuchs , Jean Jacques Bienaime , Jeffrey Robert Ajer , Mark J Alles , Richard A Meier and V Bryan Lawlis . View institutional ownership trends .

How do I buy shares of BioMarin Pharmaceutical?

Shares of BMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:BMRN

BioMarin Pharmaceutical (BMRN) Stock Price, News & Analysis

→ Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad)

Free BMRN Stock Alerts

$91.51

-0.71 (-0.77%)

(As of 04/15/2024 ET)

Compare

Today's Range: $90.97
▼
$93.35
50-Day Range: $83.81
▼
$92.22
52-Week Range: $76.02
▼
$100.38

Volume: 1.94 million shs
Average Volume: 1.36 million shs
Market Capitalization: $17.27 billion

P/E Ratio: 103.99
Dividend Yield: N/A
Price Target: $107.61

Get BioMarin Pharmaceutical alerts:

BioMarin Pharmaceutical MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.63 Rating Score
Upside/Downside: 17.6% Upside
$107.61 Price Target
Short Interest: Healthy
1.62% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -2.93
Upright™ Environmental Score
News Sentiment: 0.53
Based on 11 Articles This Week
Insider Trading: Selling Shares
$9.06 M Sold Last Quarter
Proj. Earnings Growth: 48.70%
From $1.93 to $2.87 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.63 out of 5 stars

Medical Sector

72nd out of 929 stocks

Pharmaceutical Preparations Industry

24th out of 424 stocks

3.3

Analyst's Opinion

Consensus Rating
BioMarin Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on 12 buy ratings, 7 hold ratings, and no sell ratings.
Amount of Analyst Coverage
BioMarin Pharmaceutical has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
1.62% of the outstanding shares of BioMarin Pharmaceutical have been sold short.
Short Interest Ratio / Days to Cover
BioMarin Pharmaceutical has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in BioMarin Pharmaceutical has recently increased by 3.38%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
BioMarin Pharmaceutical does not currently pay a dividend.
Dividend Growth
BioMarin Pharmaceutical does not have a long track record of dividend growth.

3.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
BioMarin Pharmaceutical has received a 35.96% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Galsulfase", "Laronidase", and "Cerliponase alfa" products. See details.
Environmental Sustainability
The Environmental Impact score for BioMarin Pharmaceutical is -2.93.

2.0

News and Social Media Coverage

News Sentiment
BioMarin Pharmaceutical has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 11 news articles for BioMarin Pharmaceutical this week, compared to 6 articles on an average week.
Search Interest
Only 8 people have searched for BMRN on MarketBeat in the last 30 days. This is a decrease of -62% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added BioMarin Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BioMarin Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,062,967.00 in company stock.
Percentage Held by Insiders
Only 1.84% of the stock of BioMarin Pharmaceutical is held by insiders.
Percentage Held by Institutions
98.71% of the stock of BioMarin Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for BioMarin Pharmaceutical are expected to grow by 48.70% in the coming year, from $1.93 to $2.87 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of BioMarin Pharmaceutical is 103.99, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 142.20.
Price to Earnings Ratio vs. Sector
The P/E ratio of BioMarin Pharmaceutical is 103.99, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 248.74.
Price to Earnings Growth Ratio
BioMarin Pharmaceutical has a PEG Ratio of 1.76. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
BioMarin Pharmaceutical has a P/B Ratio of 3.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Biden replacement revealed?

A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.

See his shocking evidence in this new report

About BioMarin Pharmaceutical Stock (NASDAQ:BMRN)

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

BMRN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BMRN Stock News Headlines

April 13, 2024 | insidertrades.com

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CAO Erin Burkhart Sells 2,286 Shares

April 2, 2024 | insidertrades.com

Insider Selling: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) EVP Sells 24,602 Shares of Stock

April 15, 2024 | Crypto Swap Profits (Ad)

Did You Get Your Free Bitcoin Yet?

And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

March 17, 2024 | insidertrades.com

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Director Sells $85,510.00 in Stock

March 17, 2024 | insidertrades.com

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Insider Henry J. Fuchs Sells 35,341 Shares

April 14, 2024 | americanbankingnews.com

Erin Burkhart Sells 2,286 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Stock

April 14, 2024 | americanbankingnews.com

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Average Recommendation of "Moderate Buy" by Brokerages

April 13, 2024 | ca.investing.com

Merck, Vertex could beat expectations despite more subdued 1Q biopharma earnings anticipated: BofA

April 15, 2024 | Crypto Swap Profits (Ad)

Did You Get Your Free Bitcoin Yet?

April 12, 2024 | finance.yahoo.com

Insider Sell: Biomarin Pharmaceutical Inc (BMRN) Chief Accounting Officer Erin Burkhart ...

April 10, 2024 | prnewswire.com

BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET

April 1, 2024 | finance.yahoo.com

Insider Sell: EVP, Chief Legal Officer George Davis Sells 24,602 Shares of Biomarin ...

March 15, 2024 | stocknews.com

3 B-Rated Biotech Stocks to Boost Your Bottom Line

March 15, 2024 | finance.yahoo.com

BMRN May 2024 90.000 call

March 12, 2024 | prnewswire.com

New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting

March 11, 2024 | finance.yahoo.com

BioMarin Pharmaceutical: Pioneering Innovations Are Driving Future Growth

March 8, 2024 | finance.yahoo.com

Insider Sell: President, Worldwide R&D Henry Fuchs Sells 35,341 Shares of Biomarin ...

March 7, 2024 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: BioMarin Pharmaceutical (BMRN) and Andlauer Healthcare Group (OtherANDHF)

March 7, 2024 | prnewswire.com

BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer

March 7, 2024 | prnewswire.com

BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer

March 1, 2024 | markets.businessinsider.com

Buy Rating Justified by BioMarin’s Strategic R&D and Voxzogo’s Market Potential

March 1, 2024 | prnewswire.com

BioMarin Scheduled to Participate in March Investor Conferences

February 29, 2024 | seekingalpha.com

BioMarin Pharmaceutical: Still Has A Lot Of Room For Growth

February 27, 2024 | bizjournals.com

Justice Department targets another Bay Area drug maker's sponsored testing program

February 27, 2024 | finance.yahoo.com

Decoding Biomarin Pharmaceutical Inc (BMRN): A Strategic SWOT Insight

February 26, 2024 | msn.com

DOJ reportedly subpoenas BioMarin over sponsored testing programs

February 26, 2024 | reuters.com

BioMarin Pharma gets DOJ subpoena on sponsored testing programs for two therapies

See More Headlines

Receive BMRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/22/2024
Today: 4/15/2024
Next Earnings (Confirmed): 4/24/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:BMRN
CUSIP: 09061G10
CIK: 1048477
Web: www.bmrn.com
Phone: (415) 506-6700
Fax: 415-382-7889
Employees: 3,401
Year Founded: 1997

Price Target and Rating

Average Stock Price Target: $107.61
High Stock Price Target: $185.00
Low Stock Price Target: $78.00
Potential Upside/Downside: +17.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.63
Research Coverage: 19 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.88
Trailing P/E Ratio: 103.99
Forward P/E Ratio: 47.41
P/E Growth: 1.76
Net Income: $167.65 million
Net Margins: 6.93%
Pretax Margin: 7.79%
Return on Equity: 5.01%
Return on Assets: 3.64%

Debt

Debt-to-Equity Ratio: 0.12
Current Ratio: 2.51
Quick Ratio: 1.57

Sales & Book Value

Annual Sales: $2.42 billion
Price / Sales: 7.14
Cash Flow: $1.78 per share
Price / Cash Flow: 51.55
Book Value: $26.29 per share
Price / Book: 3.48

Miscellaneous

Outstanding Shares: 188,734,000
Free Float: 185,261,000
Market Cap: $17.27 billion
Optionable: Optionable
Beta: 0.31

Social Links

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Brian R. Mueller (Age 50)
CFO & Executive VP
Comp: $1.15M
Mr. George Eric Davis (Age 53)
Executive VP, Chief Legal Officer, General Counsel & Secretary
Comp: $1.23M
Mr. Jeffrey Robert Ajer (Age 62)
Executive VP & Chief Commercial Officer
Comp: $1.18M
Dr. Henry J. Fuchs M.D. (Age 66)
Ph.D., President of Worldwide Research & Development
Comp: $1.49M
Mr. Alexander Hardy (Age 55)
President, CEO & Director
Ms. Erin Burkhart
Group VP & Chief Accounting Officer
Dr. Kevin Eggan Ph.D.
Chief Scientific Officer & Senior VP of Research and Early Development
Traci McCarty
Group Vice President of Investor Relations
Ms. Humaira Serajuddin
Senior VP & Chief Marketing Officer
Ms. Amy Wireman
Executive VP & Chief People Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BMRN Stock Analysis - Frequently Asked Questions

Should I buy or sell BioMarin Pharmaceutical stock right now?: 19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last twelve months. There are currently 7 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BMRN shares.
View BMRN analyst ratings or view top-rated stocks.
What is BioMarin Pharmaceutical's stock price target for 2024?: 19 equities research analysts have issued 12 month target prices for BioMarin Pharmaceutical's shares. Their BMRN share price targets range from $78.00 to $185.00. On average, they anticipate the company's stock price to reach $107.61 in the next year. This suggests a possible upside of 17.6% from the stock's current price.
View analysts price targets for BMRN or view top-rated stocks among Wall Street analysts.
How have BMRN shares performed in 2024?: BioMarin Pharmaceutical's stock was trading at $96.42 on January 1st, 2024. Since then, BMRN stock has decreased by 5.1% and is now trading at $91.51.
View the best growth stocks for 2024 here.
When is BioMarin Pharmaceutical's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024.
View our BMRN earnings forecast.
How can I listen to BioMarin Pharmaceutical's earnings call?: BioMarin Pharmaceutical will be holding an earnings conference call on Wednesday, April 24th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 609-800-9909 with passcode "1816377".
How were BioMarin Pharmaceutical's earnings last quarter?: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) posted its quarterly earnings results on Thursday, February, 22nd. The biotechnology company reported $0.49 EPS for the quarter, beating analysts' consensus estimates of $0.45 by $0.05. The biotechnology company had revenue of $646.21 million for the quarter, compared to the consensus estimate of $639.53 million. BioMarin Pharmaceutical had a trailing twelve-month return on equity of 5.01% and a net margin of 6.93%. The company's revenue for the quarter was up 20.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.11 earnings per share.

What ETFs hold BioMarin Pharmaceutical's stock?: ETFs with the largest weight of BioMarin Pharmaceutical (NASDAQ:BMRN) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), Global X Genomics & Biotechnology ETF (GNOM), First Trust NYSE Arca Biotechnology Index Fund (FBT), Goldman Sachs Future Health Care Equity ETF (GDOC), VanEck Biotech ETF (BBH), BNY Mellon Innovators ETF (BKIV), Motley Fool Mid-Cap Growth ETF (TMFM) and First Trust Innovation Leaders ETF (ILDR).
What guidance has BioMarin Pharmaceutical issued on next quarter's earnings?: BioMarin Pharmaceutical issued an update on its FY 2024 earnings guidance on Thursday, February, 22nd. The company provided earnings per share guidance of 2.600-2.800 for the period, compared to the consensus EPS estimate of 1.960. The company issued revenue guidance of $2.7 billion-$2.8 billion, compared to the consensus revenue estimate of $2.8 billion.
What is Jean-Jacques Bienaimé's approval rating as BioMarin Pharmaceutical's CEO?: 228 employees have rated BioMarin Pharmaceutical Chief Executive Officer Jean-Jacques Bienaimé on Glassdoor.com. Jean-Jacques Bienaimé has an approval rating of 94% among the company's employees. This puts Jean-Jacques Bienaimé in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at BioMarin Pharmaceutical to a friend.
What other stocks do shareholders of BioMarin Pharmaceutical own?: Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), (MDVN) (MDVN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), Vertex Pharmaceuticals (VRTX), (KITE) (KITE) and Freeport-McMoRan (FCX).
Who are BioMarin Pharmaceutical's major shareholders?: BioMarin Pharmaceutical's stock is owned by many different retail and institutional investors. Top institutional investors include Gateway Investment Advisers LLC (0.01%), Banque Cantonale Vaudoise (0.01%), Tealwood Asset Management Inc. (0.01%) and Park Avenue Securities LLC (0.00%). Insiders that own company stock include Brian Mueller, Charles Greg Guyer, Dennis Slamon, Erin Burkhart, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Mark J Alles, Richard A Meier and V Bryan Lawlis.
View institutional ownership trends.
How do I buy shares of BioMarin Pharmaceutical?: Shares of BMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BMRN) was last updated on 4/15/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial